HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Use of Expert Opinions On Supplement Ad Claim Support Cited In Guide

This article was originally published in The Tan Sheet

Executive Summary

A "guiding principle" in the Federal Trade Commission's determination of the amount and type of evidence needed to substantiate a dietary supplement advertising claim is "what experts in the relevant area of study would generally consider to be adequate," the commission states in a business guide for supplement advertisers released Nov. 18.

You may also be interested in...

Expert: FTC Clinical Data Requirements A Likely Challenge For Medtech Companies

Medtech Insight spoke to Sidley Austin LLP partner Jeff Senger about the challenges companies may face navigating the FTC’s updated health products guidance.

Multi-Ingredient Testing, Testimonial Liability Among FTC Priorities

Formulation testing of multiple-ingredient botanical supplements may be necessary to support certain advertising claims, according to Federal Trade Commission Senior Staff Attorney Michelle Rusk

FDA Should Adopt FTC` Regulatory Policy For Supplement Claims, CRN Says

FDA should emulate the Federal Trade Commission and focus on ensuring dietary supplements make truthful and substantiated label statements instead of worrying about what constitutes an implied disease claim, Council for Responsible Nutrition Scientific and Regulatory Affairs VP Annette Dickinson, PhD, commented at an FDA meeting on structure/function claims in Washington, D.C. Aug. 4.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts